J&J notes strong sales in first quarter, as it awaits word on Covid-19 vaccine
The US (and SA) paused use of J&J’s Covid-19 vaccine last week after reports that six women had developed serious but rare blood clots in the brain after receiving the shot
20 April 2021 - 15:51
Johnson & Johnson (J&J) posted stronger-than-expected first-quarter sales, as the drugmaker awaits a ruling from US health regulators on whether use of its coronavirus vaccine can resume.
For the full year, J&J said that it expected adjusted earnings per share of $9.42 to $9.57, narrowing guidance of $9.40 to $9.60 given in January, compared with the average Wall Street estimate of $9.50. First-quarter revenue was $22.32bn, outpacing the average analyst estimate of $21.98bn...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.